Skip to main content
OpenTrials
Completed

NCT Number: NCT03811613

Photobiomodulation and Parkinson

This study aimed to assess the effects of transcranial photobiomodulation in patients with Parkinson's disease (PD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Physical Education and Sport, University of León, León, Castille and León, Spain

Loading trial locations.

About this study

Thirty-five patients with idiopathic PD were randomly assigned to a photobiomodulation (n=17, [mean±SD] 72±7 years) or sham group (n=18, 70±8 years) during 9 weeks (2 sessions/week). The primary endpoint was the motor portion of the Movement Disorders Society-United PD Rating Scale. Secondary endpoints were the Scales for Outcomes in PD, static posturography, walking ability (ten-meter walk test [TMWT]) and functional mobility (timed up and go [TUG] test).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Having been diagnosed with idiopathic PD.
  • Stage 1-2 on the Hoehn and Yahr Scale.
  • Having no neurological condition other than PD.
  • Being able to stand for 2 minutes and walk 10 meters without assistance.
  • Having no severe dyskinesias or "ON-OFF" phases.

Exclusion criteria

  • Do not follow inclusion criteria.

Treatment and study plan

Transcranial photobiomodulation

Other

Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Other names: LEDs

Primary outcomes

  1. The motor portion of the MDS-UPDRS.

    Time frame: 9 weeks

    The motor portion (part III) Movement Disorders Society-Unified PD Rating Scale. It assesses the motor signs of Parkinson´s disease (minimum and maximum score is 0 and 76 points respectively -the higher score, the higher movement disorder and vice versa-).

Secondary outcomes

  1. Motor function

    Time frame: 9 weeks

    The Spanish-validated version of the Short Parkinson's Evaluation Scale (SPES)/Scales for Outcomes in PD (SCOPA). It measures the Parkinson´s disease patients motor function (minimum and maximum score is 0 and 63 points respectively -the higher score, the worse motor function and vice versa-).

  2. Static posturography

    Time frame: 9 weeks

    The centre of pressure (CoP) parameters (these CoP parameters; Length in mm, Area in mm2 and Speed in m/s are combined to report the static posturography).

  3. Walking speed

    Time frame: 9 weeks

    Ten-meter walk test

  4. TUG

    Time frame: 9 weeks

    Timed up and go test

Sponsors and collaborators

Lead sponsor

University of Oviedo

Other

Registry information

Official study title

Photobiomodulation in Parkinson´s Disease: A Randomized Controlled Trial.

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 22, 2019
Registry last updated
May 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.